(Source: Intra-Cellular Therapies Inc) NEW YORK, June 28, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that, following communication with the U.S. Food and Drug Administration (FDA), the Company has initiated Phase 3 development of ITI-007 for the treatment of agitation in patients with dementia, including Alzheimer's disease (AD). 'I am pleased to announce the advancement of ITI-007 into Phase 3 development for the treatment of behavioral disturbances associated with dementia as we continue in our mission to provide improved treatment...
↧